



**BlueCross BlueShield
of New Mexico**

COVID-19: FAQs for Medicare Providers

May 8, 2020; updated May 20, 2021

Our response to COVID-19 continues to evolve as we work to best serve our members and providers. Blue Cross and Blue Shield of New Mexico (BCBSNM) will continue to follow the applicable guidelines from the [New Mexico Department of Health](#) and [Centers for Medicare & Medicaid Services \(CMS\)](#) as appropriate for our members.

These FAQs refer to our Medicare members' access to care and other information during the Public Health Emergency, unless otherwise noted. Unless otherwise specifically described below, this information applies to our members in these individual and group Medicare (excluding Part D) and Medicare Supplement plans:

- **Blue Cross Group Medicare Advantage (HMO)SM**
- **Blue Cross Group Medicare Advantage (PPO)SM**
- **Blue Cross Group Medicare Advantage Open Access (PPO)SM**
- **Blue Cross Medicare Advantage HMO**
- **Blue Cross Medicare Advantage Dual Care (HMO SNP)SM**
- **Blue Cross Medicare Advantage (PPO)SM**
- **Blue Medicare SupplementSM**

Please visit our [Provider Information on COVID-19 Coverage](#) page and [News and Updates](#) for additional announcements.

1. [COVID-19 testing](#)
2. [COVID-19 vaccines](#)
3. [COVID-19 treatment](#)
4. [Telehealth](#)
5. [Pharmacy](#)
6. [More resources](#)

COVID-19 Testing for Medicare Members

Does BCBSNM cover the cost of testing for COVID-19 for Medicare members?

Yes. Medicare (excluding Part D) members won't pay copays, deductibles or coinsurance for lab tests to diagnose COVID-19. For Medicare Supplement members, these costs are covered by Original Medicare. Providers don't have to ask BCBSNM for approval to test for COVID-19. Testing must be for individualized diagnosis or treatment of COVID-19, medically appropriate and in accordance with generally accepted standards of care.

Does BCBSNM cover the cost of testing-related visits for COVID-19 for Medicare members?

Yes. Medicare (excluding Part D) and Medicare Supplement members won't pay copays, deductibles or coinsurance with in-network providers for testing-related visits related to COVID-19, including visits at a



provider's office, urgent care clinic, emergency room and by telehealth. Medicare Supplement members do not have network restrictions unless otherwise noted by their plan terms.

Which labs should I use for testing?

Network physicians are encouraged, and pursuant to their network contracts may be required, to refer our members to participating, in-network providers. Check our online [Provider Finder®](#) for currently contracted labs that are in-network for each patient, according to details of the member's benefit plan.

How should I code COVID-19 testing claims?

If you are collecting a COVID-19 sample from a member, submit the claim using the appropriate collection or lab code. Testing must be for individualized diagnosis or treatment of COVID-19, medically appropriate and in accordance with generally accepted standards of care, including the Centers for Disease Control (CDC) guidance as appropriate.

COVID-19 Collection Codes

- **C9083** For use by hospital outpatient departments and physician offices: Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) any specimen source
- **G2023** For use by independent clinical diagnostic labs: Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source
- **G2024** For use by independent clinical diagnostic labs: Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source

COVID-19 Lab Codes

- **0202U** Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR
- **0223U** Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected
- **0225U** Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
- **0226U** Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum
- **0240U** Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected
- **0241U** Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected
- **87426** Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])



BlueCross BlueShield of New Mexico

- **87248** Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
- **87635** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique
- **87636** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
- **87637** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
- **87811** Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
- **U0001** CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel
- **U0002** 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC
- **U0003** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R
- **U0004** 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R
- **U0005** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection

See the [American Medical Association \(AMA\) website](#) and [Billing and Coding Guidance FAQs](#) on the CMS website for more information.

Does BCBSNM cover at-home tests?

We cover at-home collection methods for COVID-19 testing if the tests are authorized by the Food and Drug Administration (FDA), and are clinically indicated for the member. We encourage members to consult with their health care provider to determine whether the test is medically appropriate for their condition.

How should I code claims for COVID-19 antibody testing?

Submit claims for COVID-19 antibody testing to us using the appropriate code. Member cost-share will be waived during the public health emergency for antibody tests that are FDA-authorized, including tests with Emergency Use Authorization (EUA), regardless of the diagnosis. Antibody testing should be medically appropriate for the member and ordered by a health care provider. Antibody tests must be FDA-authorized, including EUA. Medical or invoice records may be requested to support if an antibody test is FDA-authorized or if EUA approval has been requested.

COVID-19 Antibody Testing Codes

- **0224U** Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed
- **86318** Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step



BlueCross BlueShield of New Mexico

method

- **86328** Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method, severe acute respiratory syndrome coronavirus (SARS-CoV-2) (Coronavirus disease COVID-19)
- **86408** Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen
- **86409** Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer
- **86413** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative
- **86769** Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] [Coronavirus disease {COVID-19}] testing via multiple-step method

How should I code claims for COVID-19 testing- and antibody-related services?

To indicate services performed in conjunction with the testing for COVID-19 or COVID-19 antibodies, include one of the following diagnosis codes:

COVID-19 Diagnosis Codes

- **U07.1** COVID-19 acute respiratory disease
- **B97.29** Other coronavirus as the cause of diseases classified elsewhere
- **B34.2** Coronavirus infection, unspecified
- **Z03.818** Encounter for observation for suspected exposure to other biological agents ruled out (possible exposure to COVID-19)
- **Z11.52** Encounter for screening for COVID-19
- **Z20.822** Contact with and (suspected) exposure to COVID-19
- **Z20.828** Contact with and suspected exposure to other viral communicable diseases (actual exposure to COVID-19)

Modifier CS for testing-related services

Providers should use the CS modifier on applicable claim lines to identify the service as subject to the cost-sharing waiver for COVID-19. This is for testing-related services that result in an order for or administration of COVID-19 testing or antibody testing. Use the CS modifier only on the [codes specified by CMS](#). The following types of claims do not need the CS modifier:

- Screenings before procedures that aren't related to COVID-19; the COVID-19 test should be billed on a separate claim from the non-COVID-19 services, which will be processed according to the member's benefit plan
- COVID-19 tests
- Treatment of COVID-19

How much will I be reimbursed for diagnostic testing?

We will follow CMS pricing and apply the applicable terms of our provider and/or network participation agreements.

- **Out-of-network providers** will be reimbursed according to CMS reimbursement rates.
- Note: For providers who negotiated a nonstandard reimbursement for labs as part of their participation agreement with BCBSNM, that contracted reimbursement rate may apply.

COVID-19 Vaccines for Medicare Members

Is the COVID-19 vaccine and its administration covered for Medicare members?

Yes. For 2020 and 2021, Medicare payment for the COVID-19 vaccine and its administration will be through the original fee-for-service Medicare program. Members will have no cost-sharing on vaccines through Dec.



**BlueCross BlueShield
of New Mexico**

31, 2021.

Providers should submit claims for administering the COVID-19 vaccine to the CMS Medicare Administrative Contractor (MAC) using product-specific codes for each vaccine approved. Learn more about [vaccines and coverage](#).

COVID-19 Treatment for Medicare Members

How is treatment for COVID-19 covered for Medicare members?

Treatment of COVID-19 is covered in accordance with the member's benefit plan. We temporarily waived member cost-sharing for COVID-19 treatments through Dec. 31, 2020. Effective Jan. 1, 2021, copays, deductibles and coinsurance apply.

Members should confirm whether their benefit plan covers services received from out-of-network providers. Medicare Supplement members do not have network restrictions unless otherwise noted by their plan terms. Members should call the number on their ID card for answers to specific benefit questions.

How should I check Medicare member benefits and eligibility?

Providers may use the [Availity® Provider Portal](#) or their preferred vendor to confirm member coverage and benefits.

- However, to verify telehealth coverage, providers should call the number on the back of the member ID card or Provider Customer Service at 888-349-3706 for individual and 877-299-1008 for group to speak with a Customer Advocate. [\(Click here for more details on telehealth.\)](#)

If a Medicare member is quarantined at home, will BCBSNM cover provider visits to the home?

Home visits, if available and offered, will be covered consistent with the member's medical benefits.

Is BCBSNM extending current prior authorizations for Medicare Advantage members?

No. BCBSNM temporarily extended approvals on services with existing prior authorizations until Dec. 31, 2020, for Medicare Advantage members. This applied to services that were originally approved or scheduled between Jan. 1 and June 30, 2020.

How does the Diagnosis Related Group (DRG) add-on payment apply to providers?

For discharges of members diagnosed with COVID-19, the weight of the assigned DRG has temporarily increased 20 percent. We will apply the temporary increase, as appropriate and where consistent with network contracts, for Medicare Advantage providers. Providers should use the appropriate diagnosis code and date of discharge to identify these members:

- **B97.29** (Other coronavirus as the cause of diseases classified elsewhere) for discharges occurring on or after January 27, 2020, and on or before March 31, 2020.
- **U07.1** (COVID-19) for discharges occurring on or after April 1, 2020, through the emergency period.

How is BCBSNM responding to the suspension of the Medicare sequestration?

The Medicare sequester has been suspended until Dec. 31, 2021 (previously March 31, 2021). During this time, BCBSNM is suspending the 2% sequestration reduction in Medicare claims payments. This applies to Medicare providers who service Medicare Advantage members.



BlueCross BlueShield of New Mexico

How should a claim be rendered by a temporary provider, or “locum”?

Locum refers to physicians and advanced practice clinicians who fill in for other staff on a temporary basis. BCBSNM recognizes the efforts of temporary providers willing to help during the COVID-19 outbreak.

To expedite claims, these individuals – including medical doctor/midlevel retirees, affiliate and aligned providers and those with out-of-state licenses – should be billed using this process:

- All claims must include the rendering provider’s National Provider ID (NPI)
- Locum claims for medical doctors should be billed under one supervising medical doctor
 - Example: Locum claims for an MD should be billed under one name and rendering NPI# of the currently contracted MD for your tax ID#
- Locum claims for midlevels (APNs, RNs., etc.) should be billed under one supervising midlevel
 - Example: Locum claims for midlevels should be billed under one name and rendering NPI# of the currently contracted midlevel for your tax ID#
- All locum claims must contain a **Q6 modifier** at the claim line level

Due to COVID-19, will BCBSNM appeals procedures change?

We have temporarily adopted flexibilities in our appeals procedures to serve our Medicare members, in accordance with CMS guidance. If you have questions about claims or appeals, please call the number on the back of the member ID card or Provider Customer Service at 888-349-3706 for individual and 877-299-1008 for group to speak with a Customer Advocate

Telehealth for Medicare Members

What telehealth services are covered for Medicare members?

CMS identifies [covered services for Medicare](#) members. This means we will cover all the [CMS telemedicine codes](#), including those available only during the PHE for Medicare Advantage and Medicare Supplement members. Care must be consistent with the terms of the member’s benefit plan.

For the duration of the PHE, we are waiving cost share for our Medicare Advantage members for telehealth visits. This means these members will not owe any copays, deductibles or coinsurance for telehealth visits. The cost share waiver does not apply to Medicare Supplement members. Members should call the number on their ID card if they have questions.

Which providers may provide telehealth services to Medicare members?

Providers of telehealth may include, but are not necessarily limited to:

- Physicians
- Physician assistants
- APRNs
- CMS-recognized, licensed behavioral health and applied behavioral analysis service providers
- Physical therapy, occupational therapy and speech therapy service providers

See CMS’ [telehealth guidance](#) and [Waivers and Flexibilities](#) for more details.

How should I check Medicare members’ benefits and eligibility for telehealth?

- Call our Provider Services to check eligibility and office visit benefits by calling the number on the back of the member ID card or Provider Customer Service at 888-349-3706 for individual and 877-299-1008 for group to speak with a Customer Advocate. (Telehealth is not yet a category offered in our automated Interactive Voice Response (IVR) phone system.)
- Verify general coverage by submitting an electronic 270 transaction. This step will help providers determine coverage information, network status, benefit prior authorization/pre-



BlueCross BlueShield of New Mexico

notification requirements and other important details.

Visit the CMS website for a [complete list of telehealth codes](#).

Can I provide telehealth services to new and established Medicare patients?

Yes. CMS currently is not requiring Medicare providers to have treated a patient in the previous three years to provide telehealth services. Providers can now engage in telehealth services with new Medicare patients.

Can I conduct Medicare members' annual health assessments by telehealth?

Initial and subsequent Annual Wellness Visits (G0438 and G0439) may be conducted by telehealth. Submit claims for wellness visits with Modifier 95 and Place of Service (POS) 11. BCBSNM covers one wellness visit every calendar year.

- **Note: CMS has not approved Initial Preventive Physical Examinations (IPPE) (G0402) for telehealth.** Members are eligible for the IPPE during their first 12 months of enrollment in Medicare.

Are prior authorizations required for telehealth visits?

Some telemedicine care will require referrals and prior authorizations in accordance with the member's benefit plan. If you have questions about prior authorizations, please use [Availity Authorizations](#).

How can telehealth be conducted for Medicare members?

Providers should use an interactive audio and video telecommunications system that permits real-time interactive communication to conduct telehealth services. CMS permits audio only in limited circumstances. See the CMS website for [designated audio-only codes](#).

Providers can find the latest guidance on acceptable HIPAA-compliant remote technologies issued by the [U.S. Department of Health and Human Services' Office for Civil Rights in Action](#).

How should I code telehealth claims?

Submit claims for medically necessary services delivered via telemedicine with the appropriate modifiers (95, GT, GQ, G0) and Place of Service (POS) 02.

We accept the following modifiers:

- 95 – synchronous telemedicine (two-way live audio visual)
- GT – interactive audio and video telecommunications
- GQ – asynchronous
- G0 – telemedicine services for diagnosis, evaluation or treatment of symptoms of an acute stroke; G0 must be billed with one of the approved telemedicine modifiers (GT, GQ or 95)

Visit the CMS website for a [complete list of telehealth codes](#) and [telehealth guidance](#).

How will I be reimbursed for telehealth claims?

Currently telehealth claims for insured members for in-network medically necessary covered health care services will be reimbursed at the same rate as in-person office visits. Submit claims with appropriate codes and modifiers.

- **Out-of-network providers:** We reimburse out-of-network providers according to the CMS reimbursement rates. Please call the customer service number on the member's ID card for benefit information.



Pharmacy for Medicare Members

How is BCBSNM helping with prescriptions?

Members of these Medicare plans can get 90-day fills through mail order.

- Blue Cross Group Medicare Advantage (HMO)
- Blue Cross Group Medicare Advantage (PPO)
- Blue Cross Group Medicare Advantage Open Access (PPO)
- Blue Cross Group MedicareRx (PDP)SM
- Blue Cross Medicare Advantage HMO/HMOSNP
- Blue Cross Medicare Advantage HMO/HMOPOS
- Blue Cross Medicare Advantage (PPO)
- Blue Cross MedicareRx (PDP)SM
- Blue Cross Medicare Advantage Dual Care (HMO SNP)

All pharmacy practice safety measures, as well as prescribing and dispensing laws, remain in force and effect.

More Resources

Continue to watch the [News and Updates](#) section of the BCBSNM website for updates. If you have additional questions, contact Provider Customer Service at 888-349-3706.

CMS

- General: <https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPRO/Current-Emergencies/Current-Emergencies-page>
- Fact Sheets and News Alerts: <https://www.cms.gov/newsroom>
- Telehealth Services: <https://www.cms.gov/Medicare/Medicare-General-Information/Telehealth/Telehealth-Codes>

CDC

- General: <https://www.cdc.gov/nCoV>
- Health Care Professionals: <https://www.cdc.gov/coronavirus/2019-nCoV/guidance-hcp.html>
- Information for Laboratories: <https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html>
- Laboratory Biosafety: <https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html>
- Specimen Collection: <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>

U.S. Food and Drug Administration (FDA)

- General: <https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19>
- Emergency Use Authorizations: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>

This material is for informational and educational purposes only. It is not intended to be a definitive source for coding claims. Health care providers are instructed to submit claims using the most appropriate code(s) based upon the medical record documentation and coding guidelines and reference materials. This material is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. References to third party sources or organizations are not a representation, warranty or endorsement of such organizations. Any questions regarding those organizations should be addressed to them directly. The fact that a service or




BlueCross BlueShield of New Mexico

treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider. Prior authorization for health care services is not a guarantee of payment.

Checking eligibility and/or benefit information and/or the fact that a service has been preauthorized/pre-notified is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member's certificate of coverage applicable on the date services were rendered. If you have any questions, call the number on the member's ID card.

CPT copyright 2021 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSNM. BCBSNM makes no endorsement, representations or warranties regarding any products or services provided by third party vendors such as Availity. If you have any questions about the products or services provided by such vendors, you should contact the vendor(s) directly.

 By clicking this link, you will go to a new website/app ("site"). This new site may be offered by a vendor or an independent third party. The site may also contain non-Medicare related information. In addition, some sites may require you to agree to their terms of use and privacy policy.